UK Compliance
Statement

The Catalyst Clinic is a private medical advisory clinic operating from 96 Kensington High Street, London W8 4SG, with additional locations in New York (154 Grand St, 5th Floor, NY 10013) and Zürich (Bahnhofstrasse 10, 8001).

The Catalyst Clinic provides private physician-led advisory consultations. All clinical programmes are designed, overseen, and conducted by a qualified physician team. Our UK clinical operations are conducted under the oversight of our GMC-registered physician team in compliance with General Medical Council (GMC) standards of professional practice.

Lead physician and founder: Dr. Ethan Hausman-Marquis — PhD in Cell and Genomic Biology, doctor-scientist, US Board-Certified in Regenerative Medicine, European Board-Certified in Longevity Medicine, Member of the American Academy of Anti-Aging Medicine (A4M), and author of two published works in peptide science.

The Catalyst Clinic provides private medical advisory consultations only. We are not a pharmacy, a treatment facility, or a provider of licensed medicinal products.

Our services involve the provision of physician-reviewed, evidence-informed advisory consultations in which clinicians discuss the current state of scientific research relating to peptide compounds. All advisory protocols are developed on the basis of mandatory comprehensive diagnostics reviewed by the consulting physician.

Where compounds are made available through the relevant prescribing pathway and are clinically appropriate, patients may be directed to GMP-certified, EMA-regulated, and FDA-registered compounding pharmacies. The compounds themselves are dispensed independently by those pharmacies — not by The Catalyst Clinic.

The peptide compounds discussed at The Catalyst Clinic — including but not limited to BPC-157, TB-500, GHK-Cu, CJC-1295, Ipamorelin, Epithalon, Semax, Selank, NAD+, MOTS-c, KPV, Sermorelin, Humanin, Thymosin Alpha-1, Tesamorelin, LL-37, Cerebrolysin, VIP, and MK-677 — are not licensed medicines under the Human Medicines Regulations 2012.

Under UK law, unlicensed medicines may be discussed and advised upon by GMC-registered physicians within the framework of a private medical consultation where there is a clinical rationale to do so. This is known as the "specials" provision and operates under the prescribing discretion afforded to registered medical practitioners under the Medicines Act 1968 and subsequent regulations.

The Catalyst Clinic operates exclusively within this legal framework. No compounds are sold, dispensed, or administered by The Catalyst Clinic directly.

The Catalyst Clinic designs and reviews all clinical operations, communications, and marketing in reference to the following regulatory bodies and frameworks:

Where compounds are made available through advisory protocols, they are sourced exclusively through compounding pharmacies that meet all of the following standards:

• GMP-Certified — Good Manufacturing Practice certification, ensuring consistent production quality, purity, and sterility standards
• EMA-Regulated — European Medicines Agency regulatory oversight, applicable to EU-based compounding facilities
• FDA-Registered — United States Food and Drug Administration registration, applicable to US-based compounding facilities
• Certificate of Analysis — Every compound order is accompanied by a third-party certificate of analysis confirming identity, purity, and potency

The Catalyst Clinic does not work with unregulated research chemical suppliers, grey-market peptide vendors, or any source that cannot provide a certificate of analysis. This is a non-negotiable standard applied to every patient programme without exception.

The Catalyst Clinic applies the following clinical standards to every patient programme:

• Mandatory pre-consultation diagnostics — Comprehensive bloodwork is required before any advisory protocol is discussed. No programme is designed without baseline biomarker data.
• Personal physician review — All diagnostic results are reviewed by the consulting physician personally. No algorithmic or delegated review processes are used for protocol design.
• Ongoing monitoring — Monthly physician reviews and repeat diagnostics every four to five months throughout the programme. Clinical oversight does not end after the initial consultation.
• Medication interaction screening — All potential interactions between discussed compounds and current medications are reviewed as part of the consultation process.
• Full documentation — All clinical decisions are documented, explained, and traceable within the patient record.
• Informed consent — Patients receive a full explanation of the advisory nature of the consultation, the legal status of compounds discussed, and the current state of scientific evidence before any programme begins.

All marketing communications by The Catalyst Clinic adhere to the CAP (UK) Code administered by the ASA. Specifically:

• No efficacy claims are made for any compound discussed. Language relating to scientific research is framed in terms of what is "studied", "investigated", or "researched" — not what is proven or established in humans.
• No before-and-after claims or testimonials implying guaranteed or typical outcomes are used.
• No comparative claims suggesting superiority over licensed medicines or other clinics are made without substantiation.
• All references to scientific research are presented in an investigational context and do not constitute endorsement of efficacy.
• Price references include all mandatory fees where required by applicable advertising standards.

For the avoidance of doubt, The Catalyst Clinic does not:

• Diagnose, treat, cure, or prevent any medical condition
• Dispense, sell, or administer pharmaceutical compounds directly to patients
• Prescribe licensed medicines (except where our GMC-registered physician team exercises standard prescribing discretion within a regulated private medical consultation)
• Guarantee, imply, or represent any specific outcome from any advisory programme
• Operate as a pharmacy or pharmaceutical distributor
• Source compounds from unregulated, grey-market, or uncertified suppliers
• Provide advisory consultations to individuals under the age of 18
• Provide advisory consultations without mandatory pre-consultation diagnostics

Patients engaging with The Catalyst Clinic are responsible for:

• Providing accurate and complete medical history, medication lists, and health information prior to and during their consultations
• Informing their GP or primary care physician of any advisory programmes they are participating in
• Verifying their own regulatory and sporting compliance where applicable (e.g., WADA status for competitive athletes)
• Understanding that compounds discussed are not licensed medicines and are the subject of ongoing research only
• Promptly reporting any adverse reactions or unexpected changes in health status to The Catalyst Clinic and their GP

For any questions regarding this compliance statement, our regulatory approach, or the legal basis of our services, please contact:

If you have a complaint about our services, clinical conduct, or advertising communications, you may also contact the relevant regulatory body directly:

• ASA (advertising complaints) — asa.org.uk
• GMC (clinical conduct complaints) — gmc-uk.org
• MHRA (medicines regulation) — gov.uk/mhra
• ICO (data protection) — ico.org.uk

This compliance statement is reviewed and updated periodically. The date of last update is shown in the header of this document. The Catalyst Clinic reserves the right to amend this statement at any time. Continued use of our services following any update constitutes acceptance of the revised statement.